MK-2048

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

MK-2048 是 HIV-1 整合酶 (IN) 和 IN 突变体 R263K 的有效抑制剂，IC50 分别为 2.6 nM 和 1.5 nM。

MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively; inhibits subtype B and subtype C integrase activities with IC50 of 75 nM and 80 nM, respectively; inhibits S217H intasome with an IC50 of 900 nM, remains fully active against the N224H intasome with IC50 of 25 nM.,displays substantially lower dissociation rates compared with raltegravir, another integrase inhibitor.HIV Infection Phase 1 Clinical.

——

——

MK 2048 | MK2048

Microbiology/Virology

HIV

Integrase|Integrase(R263K)

Infection

HIV Infection

869901-69-9

461.8784

C21H21ClFN5O4

>98% (HPLC)

10 mM in DMSO

O=C(C(C1=C2C(O)=C3N1[C@@H](C)CN(CC)C3=O)=NN(CC4=CC=C(F)C(Cl)=C4)C2=O)NC

Pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)-

(-20℃)

With Ice Pack

≥ 2 years